Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protandim
- Development stage
- Unknown
- Lead developer
- LifeVantage
- Administration
- Oral
01
Overview
Protandim is a multi-ingredient dietary supplement marketed by LifeVantage Corporation, primarily known as the "Protandim Nrf2 Synergizer." It consists of a proprietary blend of five botanical extracts: milk thistle (Silybum marianum), bacopa (Bacopa monnieri), ashwagandha (Withania somnifera), green tea (Camellia sinensis), and turmeric (Curcuma longa). The supplement is designed to activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway, a key cellular mechanism for regulating the antioxidant response. By activating Nrf2, Protandim induces the production of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, which help mitigate oxidative stress. It is being evaluated in clinical research, such as the Duke University-led ROAR-DIGAP trial, as a personalized treatment for Amyotrophic Lateral Sclerosis (ALS) patients identified with high oxidative stress biomarkers.
- Brand names
- ProtandimProtandim Nrf2 Synergizer
- Other names
- Nrf2 SynergizerNrf-2 SynergizerNrf 2 Synergizer
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on Protandim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protandim.